Phase II study of pre-emptive therapy against CMV-associated disesase by valganciclovir after allogeneic hematopoietic stem cell transplantation

Phase II study of pre-emptive therapy against CMV-associated disesase by valganciclovir after allogeneic hematopoietic stem cell transplantation - Pre-emptive therapy against CMV-associated disesase by valganciclovir after allogeneic hematopoietic stem cell transplantation

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000000953

Enrollment

Registered

2008-04-01

Start date

2007-06-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients with CMV reactivation after allogeneic hematopoietic stem cell transplantation

Interventions

valganciclovir

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: After allogeneic BM/PBSC transplantation CMV reactivation (CMV C7-HRP >= 2/50,000 WBCs) No CMV-associated disease Pts can take medicine by peroral PS 0-2 No major organ complication

Exclusion criteria

Exclusion criteria: Negative CMV-Ab of both donor and recipient cord blood transplantion T-cell depleted or CD34-positive cell selected transplantion Gut GVHD (>=stage 2) HLA more than 2 locus disparity

Design outcomes

Primary

Measure	Time frame
Efficacy of valganciclovir against CMV reactivation	—

Secondary

Measure	Time frame
Safety of valganciclovir after allogeneic HSCT Incidence of CMV-associated disease	—

Countries

Japan

Contacts

Public ContactKatsuto Takenaka

Kyushu University Hospital Dept of 1st Intern Med

takenaka@intmed1.med.kyushu-u.ac.jp092-642-5230

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026